Planned
There are currently no planned studies in our center.
Ongoing
There are currently no ongoing studies in our center.
Closed
XL184-311
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT03690388